New Guidance Brings Welcome Clarity on Practical Application of EU Orphan Drugs Law
Executive Summary
EU pharmaceutical companies have welcomed new European Commission guidance that provides greater clarity on how several key provisions of the legislation on orphan drugs should be applied in practice.
You may also be interested in...
New Head For EMA's Orphan Drugs Committee
A key priority for the new chair will involve reinforcing how the European Medicines Agency’s orphan drugs committee interacts and communicates with other scientific committees at the agency and other international partners.
More Checks And Balances For Orphan Drugs Needed, Says Germany’s G-BA
The German pricing and reimbursement authority wants better scrutiny of orphan drug designations and incentives for orphan drug development to help address the access problem.
Changes To EU Orphan Similarity Concept Could Change Innovation Threshold For 10-Year Exclusivity
The European Commission has proposed changes to the existing criteria used for determining whether a new medicinal product is similar to an already authorized orphan drug and, therefore, whether it can be accepted for evaluation and granted 10-year market exclusivity.